Celldex Therapeutics, Inc.

NasdaqCM:CLDX Rapporto sulle azioni

Cap. di mercato: US$2.2b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Celldex Therapeutics Gestione

Gestione criteri di controllo 2/4

Celldex Therapeutics' Il CEO è Anthony Marucci, nominato in May2003, e ha un mandato di 21.25 anni. la retribuzione annua totale è $ 8.36M, composta da 8.6% di stipendio e 91.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.043% delle azioni della società, per un valore di $ 975.84K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 8.1 anni e 11.5 anni.

Informazioni chiave

Anthony Marucci

Amministratore delegato

US$8.4m

Compenso totale

Percentuale dello stipendio del CEO8.6%
Mandato del CEO21.3yrs
Proprietà del CEO0.04%
Durata media del management8.2yrs
Durata media del Consiglio di amministrazione11.6yrs

Aggiornamenti recenti sulla gestione

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21
An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Sep 07
We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Jul 21

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Jul 14

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Celldex: Powerful Medicines To Yield Further Upsides

Jul 08

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Anthony Marucci rispetto agli utili di Celldex Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$150m

Mar 31 2024n/an/a

-US$145m

Dec 31 2023US$8mUS$721k

-US$141m

Sep 30 2023n/an/a

-US$125m

Jun 30 2023n/an/a

-US$113m

Mar 31 2023n/an/a

-US$119m

Dec 31 2022US$5mUS$693k

-US$112m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$100m

Mar 31 2022n/an/a

-US$77m

Dec 31 2021US$6mUS$669k

-US$71m

Sep 30 2021n/an/a

-US$72m

Jun 30 2021n/an/a

-US$66m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$3mUS$644k

-US$60m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$1mUS$619k

-US$51m

Sep 30 2019n/an/a

-US$50m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$50m

Dec 31 2018US$1mUS$608k

-US$151m

Sep 30 2018n/an/a

-US$146m

Jun 30 2018n/an/a

-US$165m

Mar 31 2018n/an/a

-US$177m

Dec 31 2017US$2mUS$598k

-US$93m

Compensazione vs Mercato: La retribuzione totale di Anthony ($USD 8.36M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.50M ).

Compensazione vs guadagni: La retribuzione di Anthony è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Anthony Marucci (62 yo)

21.3yrs

Mandato

US$8,361,844

Compensazione

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Anthony Marucci
Founder21.3yrsUS$8.36m0.043%
$ 947.9k
Tibor Keler
Founder21.3yrsUS$3.42m0.011%
$ 244.3k
Sam Martin
Senior VP7.2yrsUS$2.95m0.042%
$ 933.8k
Margo Heath-Chiozzi
Senior Vice President of Regulatory Affairs6.9yrsUS$2.94m0.020%
$ 444.3k
Diane Young
Senior VP & Chief Medical Officer5.3yrsUS$2.97m0.026%
$ 568.2k
Joseph Schlessinger
Co-Founder & Member of Scientific Advisory Boardno dataNessun datoNessun dato
Sarah Cavanaugh
Senior Vice President of Corporate Affairs & Administration7.3yrsNessun dato0.0028%
$ 61.8k
Freddy Jimenez
Senior VP & General Counsel3.7yrsUS$2.17m0.053%
$ 1.2m
Ronald Pepin
Chief Business Officer & Senior VP13.2yrsUS$711.26kNessun dato
Elizabeth Crowley
Chief Product Development Officer & Senior VP10.2yrsUS$1.18m0.014%
$ 301.3k
Richard Wright
Chief Commercial Officer & Senior VP9.2yrsUS$563.17k0.031%
$ 691.7k

8.2yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di CLDX è esperto e expertise (durata media dell'incarico 8.1 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Anthony Marucci
Founder15.8yrsUS$8.36m0.043%
$ 947.9k
Joseph Schlessinger
Co-Founder & Member of Scientific Advisory Board3.1yrsNessun datoNessun dato
Harry Penner
Independent Director27.7yrsUS$371.19k0.0042%
$ 92.7k
Herbert Conrad
Independent Director16.5yrsUS$364.94k0.0039%
$ 85.2k
Louis Weiner
Member of Scientific Advisory Boardno dataNessun datoNessun dato
James Marino
Independent Director7.5yrsUS$377.44k0.019%
$ 421.7k
Karen Shoos
Independent Chair of the Board of Directors23.3yrsUS$385.77k0.0042%
$ 92.4k
Carl June
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Michel Nussenzweig
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Marc Rothenberg
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Keith Brownlie
Independent Director7.3yrsUS$373.27k0.0010%
$ 22.0k
Cheryl Cohen
Independent Director2.3yrsUS$367.02k0%
$ 0

11.6yrs

Durata media

72yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CLDX è composto da personale esperto e esperto (durata media dell'incarico 11.5 anni).